
Hashtag: #IBPOGroupBerhad #FWDInsuranceBerhad #LoanFinancingProtection
The issuer is solely responsible for the content of this announcement.
IBPO Group Berhad

Hashtag: #IBPOGroupBerhad #FWDInsuranceBerhad #LoanFinancingProtection
The issuer is solely responsible for the content of this announcement.

The new grade – suitable for the production of barrier and lamination films, dairy packaging, as well as stretch films for wrapping – was developed by experts from SIBUR’s R&D centre with the direct involvement of several packaging manufacturers.
The grade, named mLL20183 FE, is comparable to foreign-made counterparts in terms of its physical and mechanical properties and has strong sales potential not only in Russia but also in international markets.
Products made from this polyethylene feature excellent sealing characteristics, strength, and tear resistance. Its improved processability enables film manufacturers to use blown film lines more efficiently. Additionally, the seamless transition between grades with different melt flow indices helps reduce operational costs.
Metallocene polyethylene is produced using metallocene catalysts (additives) based on zirconium or titanium, which enhance polymer properties, making it stronger, more transparent, and more flexible.
SIBUR produces metallocene polyethylene at the Nizhnekamskneftekhim production complex. By 2028, the company plans to fully modernise production by building a new plant capable of producing up to 300,000 tonnes of this premium polymer annually, which holds significant export potential.
Hashtag: #SIBUR
The issuer is solely responsible for the content of this announcement.
![]() |
“No.1 Meets No.1” – A Legendary Collaboration Redefining Excellence
HONG KONG, Aug. 13, 2025 /PRNewswire/ — Renowned Hong Kong heritage brand Wong To Yick Wood Lock Medicated Balm today announced its groundbreaking partnership with Cantopop Diva Joey Yung as its first-ever brand ambassador. This landmark collaboration—“No.1 Meets No.1”—showcases Wong To Yick’s undisputed leadership as Hong Kong’s No.1 Muscle Pain Reliever¹ and No.1 in the Medicated Oil Segment², while leveraging Joey Yung’s global influence to elevate the brand’s legacy of professionalism and trust to new heights.

Wong To Yick Wood Lock Medicated Balm Proudly Announces Cantopop Diva Joey Yung as Its First-Ever Brand Ambassador
[High-resolution promotional photo download: Here]
A Legendary Union: Excellence Meets Excellence
The collaboration between Wong To Yick and Joey Yung is rooted in shared values of perseverance and excellence. Wong To Yick Wood Lock Medicated Balm has dominated Hong Kong’s pain relief market for over half a century, maintaining its position as the No.1 Muscle Pain Reliever[1] and No.1 in the Medicated Oil Segment[2] (by sales volume and value) for three consecutive years. Meanwhile, Joey Yung, renowned for her unparalleled dedication and resilience, embodies the brand’s spirit of “growing stronger through challenges.”
“ Wong To Yick Wood Lock Medicated Balm has been a trusted part of my life since childhood,” shared Joey Yung. “Whether it’s post-performance muscle fatigue or soreness from daily training, it delivers fast, effective relief. My personal experience aligns perfectly with the brand’s ethos of perseverance and strength.”
Wong To Yick & Joey Yung: Join Forces to Pioneer a New Brand Era
This landmark partnership between Wong To Yick Wood Lock Medicated Balm and Cantopop music icon Joey Yung marks a transformative milestone for this Hong Kong heritage brand with over half a century of history. As the brand’s first-ever ambassador, Joey Yung will leverage her widespread influence and positive public image to help redefine Wong To Yick’s identity—breaking free from traditional Chinese medicine stereotypes and cultivating a more youthful, fashionable brand appeal.
On the marketing front, Wong To Yick will launch a comprehensive promotional campaign, including high-end TV commercials that highlight the product’s efficacy alongside Joey’s star power, large-scale outdoor advertisements to amplify brand visibility, interactive social media initiatives to engage younger consumers, and strengthened retail partnerships to ensure optimal product availability and presentation. All marketing efforts will center on the theme “Perseverance, the Champion’s Choice,” seamlessly blending Joey Yung’s superstar persona with the brand’s professional credibility—reshaping modern consumers’ perception of premium Chinese herbal remedies.
Wong To Yick places consumer trust at the forefront, particularly in combating counterfeit products. The brand has established a robust anti-counterfeiting system and will roll out multi-tiered educational initiatives, including detailed authenticity guides on official websites and social platforms, empowering consumers to identify genuine products with ease. As the ambassador, Joey Yung shared, “As a Hong Kong native, I have unwavering faith in the words ‘Made in Hong Kong.’ Wong To Yick’s decades of consistent quality reflect not just a product commitment but the very essence of Hong Kong’s spirit. Every authentic bottle embodies this dedication and integrity.”
Since its founding in 1968 by Mr. Wong To Yick, the brand has remained steadfast in its Hong Kong manufacturing roots, using premium natural herbal ingredients to uphold the highest quality standards. Looking ahead, Wong To Yick will continue to embrace its “Growing Stronger Through Challenges” ethos, innovating while honoring tradition, to deliver superior health products to global consumers—ensuring this half-century legacy of craftsmanship endures for generations to come.
[1] Sales Value (HK$) and Sales Volume (KG/LITRE) in the Muscle Pain Reliever category from Feb 2022 – Jan 2025. (Copyright © 2025, NielsenIQ)
[2] Sales Value (HK$) and Sales Volume (KG/LITRE) in the Oil segment of Muscle Pain Reliever category from Feb 2022 – Jan 2025. (Copyright © 2025, NielsenIQ)
About Wong To Yick Wood Lock Medicated Balm
Wong To Yick Wood Lock Medicated Balm: A Hong Kong Legacy Spanning Over Half a Century
Brand Heritage
“Pain stems from blockage; relief comes from flow.” This ancient Chinese medical philosophy has been the lifelong guiding principle of Mr. Wong To Yick, founder of Wong To Yick Wood Lock Medicated Balm. As an iconic Hong Kong brand established in the 1960s and now in its second generation of leadership, Wong To Yick has remained steadfast in its original mission through decades of societal change, upholding the artisan spirit of “mastering one craft with relentless dedication.”
In 1968, Mr. Wong began his journey from a humble herbal tea shop in Sham Shui Po, combining decades of medical expertise with the essence of traditional Chinese medicine. Through rigorous clinical trials and formula refinement, he developed this revolutionary liniment with unparalleled penetrating efficacy. From grassroots word-of-mouth recognition to becoming an internationally renowned authority in Chinese herbal medicine, the product’s “activate circulation, relieve pain” benefits have made it a testament to Hong Kong’s excellence in traditional medicine.
Commitment to Craftsmanship
For over 50 years, Wong To Yick Wood Lock Medicated Balm has embodied the philosophy of “a lifetime devoted to perfecting one art.” Amidst changing times, the brand maintains 100% Made-in-Hong Kong integrity, with stringent quality control across every step of production at its self-operated factories in Kwai Chung and Yuen Long. From sourcing premium global herbal ingredients to blending time-honored techniques with modern technology, each bottle undergoes 18 meticulous processes to meet international pharmaceutical standards.
The Hong Kong Spirit & Brand Promise
To Wong To Yick, “Made in Hong Kong” is more than a label—it’s an enduring pledge. For over half a century, we’ve preserved traditional medicine craftsmanship with an artisan’s heart, ensuring every bottle upholds a solemn promise to consumer well-being.
The brand is built on three core values:
As brand ambassador Joey Yung reflects, “This isn’t just a liniment—it’s the crystallization of Hong Kong ingenuity.” From a Sham Shui Po shop to global markets, Wong To Yick epitomizes the true Hong Kong spirit: upholding professional essence through change while pursuing excellence through refinement. Every drop tells the story of Hong Kong’s “do one thing perfectly” perseverance.
This commitment has made Wong To Yick Wood Lock Medicated Balm a collective memory across three generations of Hong Kongers and an indispensable safeguard in countless household medicine cabinets. We believe genuine Hong Kong spirit isn’t measured by scale, but by an unyielding dedication to quality that stands the test of time.
For media inquiries, please contact:
Wong To Yick Wood Lock Oinment Limited.
Marketing & Sales Department
Tel: +852 2409 0920 | Email: info@wongtoyick.com.hk
Official Channels:
Website: www.wongtoyick.com.hk
Facebook: https://www.facebook.com/Wongtoyick.com.hk
Instagram: https://www.instagram.com/wongtoyick/
PR Agency:
SORTIE Agency Limited
Tel: +852 2855 6896 | Email: info@sortieagency.com
![]() |
PROVIDENCIALES, Turks and Caicos Islands, Aug. 13, 2025 /PRNewswire/ — The globally leading cryptocurrency exchange KuCoin today announced a collaborative exploration with the digital financial infrastructure platform AlloyX to introduce Real-World Asset (RWA) tokens into the exchange’s collateral mechanisms. This partnership will pilot the integration of RWA token RYT, issued by a traditional licensed asset management company, into KuCoin’s Off-Exchange Settlement (OES) system for credit line management. The mechanisms will be gradually optimized and expanded based on market feedback.
This collaboration incorporates tokenized products from the “ChinaAMC USD Digital Money Market Fund,” issued by a traditional large-scale asset management institution—China Asset Management (Hong Kong) Limited—into the exchange’s credit system. It represents a new attempt to drive ongoing innovation in RWA application scenarios, further penetrating and establishing connections between Web2 and Web3 assets.
Crossover Initiative: Tokens Backed by Traditional Fund Assets Enter the Exchange Credit System
China Asset Management (Hong Kong) Limited is a wholly-owned subsidiary of China Asset Management Co., Ltd., and is one of the earliest Chinese asset management institutions in Hong Kong to conduct overseas business. It is the issuer of the underlying asset for the RYT token—the “ChinaAMC USD Digital Money Market Fund.” This fund is one of Asia’s first tokenized USD funds targeted at retail investors, with fund units available for subscription and redemption in token form.
Under this partnership mechanism, KuCoin will include RYT in its credit collateral list. Users holding the token can apply for credit lines in their platform accounts to support related trading operations. Backed by secure mechanisms and authentic assets, this innovative attempt provides a new use case for RWA tokens: users can earn underlying yields through holding, allowing investors to configure money market fund tokens as conveniently as other on-chain assets and increase asset allocation diversity, while also activating asset leverage value through collateralization.
Notably, the underlying asset structure of RYT has undergone rigorous compliance design, with functions such as fund custodian banking, fund administration, and unit registration handled by Standard Chartered Bank in Hong Kong, offering a trustworthy asset chain under a traditional financial framework.
KuCoin CEO BC Wong stated: “KuCoin has always been committed to bridging traditional finance and the crypto world through innovation. This collaboration with AlloyX to explore RWA tokens as collateral mechanisms exemplifies our dedication to providing users with secure and compliant solutions. We emphasize trustworthiness and risk control—this partnership not only elevates the platform’s innovation level but also delivers reliable asset appreciation opportunities to global users, helping them manage digital assets more confidently in dynamic markets.“
AlloyX Co-Founder and CEO Thomas Zhu remarked: “Our focus has always been on how RWA, as an asset form, can deliver more authentic and sustainable economic functions on-chain. This cooperation with KuCoin is a pragmatic attempt centered on ‘collateral mechanisms and scenario building,’ not only offering users more possibilities for asset utilization but also providing the industry with opportunities for structural validation.“
Long-Term Significance: Activating Liquidity and Guiding Market Consensus
Although RWA is still in its early development stage, its potential in institutional design, risk control, and asset-side construction is increasingly recognized by financial technology institutions. In this collaboration, AlloyX and KuCoin are linking up around RWA collateral mechanisms—not just a product-level integration test but potentially a vanguard for subsequent market standards and practical paths.
From an industry perspective, incorporating traditional asset tokens as compliant collateral into mainstream exchange credit systems is expected to enhance the depth of RWA usage and liquidity, while also providing observable models for more asset issuers, platform operators, and regulators.
In this context, KuCoin stated that it will continue to deepen exploratory collaborations with various parties to bring more innovative value to global users.
About KuCoin
Founded in 2017, KuCoin is a leading global cryptocurrency platform serving over 41 million users across 200+ countries and regions. Built on cutting-edge blockchain technology, KuCoin offers access to 1,000+ digital assets and solutions including Web3 wallet, Spot and Futures trading, institutional services, and payments. Recognized by Forbes as one of the “Best Crypto Apps & Exchanges” and a “Top 50 Global Unicorn” by Hurun, KuCoin is ISO 27001:2022 certified and committed to security, compliance, and innovation under the leadership of CEO BC Wong. Learn more: https://www.kucoin.com/
About AlloyX
AlloyX Limited is a technology company that specializes in global stablecoin payments and asset tokenization. Committed to integrating traditional banking payment systems with blockchain services, AlloyX provides secure and efficient stablecoin payment services and asset tokenization solutions. The company aims to become Asia’s leading stablecoin payments infrastructure and RWA tokenization technology provider. AlloyX offers embedded stablecoin wallet services and integrates various blockchain and payment solutions into its wallet and payment middle platform. The AlloyX platform also provides comprehensive solutions for stablecoin storage, payments, settlement, investment, foreign exchange, and asset tokenization, promoting the global adoption and application of stablecoin payments and tokenization technologies.
SINGAPORE, Aug. 13, 2025 /PRNewswire/ — KBP Biosciences Pte. Ltd. (the “Company“) today issued a statement addressing a further decision by the Singapore International Commercial Court (the “Court“) to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua (“Dr. Huang“), in support of arbitration proceedings respectively commenced by the Company and by Novo Nordisk A/S (“Novo Nordisk“).
Following the Court’s judgment today, the validity of the injunction application sought by Novo Nordisk will be determined via the arbitral process, which the Company commenced before Novo Nordisk. More importantly, in the course of judgment, the Court examined a range of issues central to the dispute, including the conduct of clinical trials and the adequacy of due diligence. The findings of the Court are subject to further scrutiny by the arbitral tribunal, which will have more time and the benefit of hearing live testimony, unlike the Court.
1. Independent Testimony by Steering Committee Members
The judgment cites to the independent statements from steering committee members comprising Dr. Bertram Pitt and Dr. Janet Wittes, who are highly distinguished and well respected in the field. These evidence include an open letter by Dr. Pitt and Dr. Wittes on December 18, 2024, stating that “neither [Novo] nor KBP has provided any convincing evidence that the results from [the Bulgaria site] are fraudulent”. That open letter was unavailable to the Court in the previous ex parte hearing.
Further, if the Bulgaria site were indeed tainted by serious irregularities and fraud, the “FDA and EME would have responded. However, they have not responded, and Novo did not disclose this” in the previous ex parte hearing.
2. Statistical Errors and the Futility Determination
Eight months after it acquired Ocedurenone, Novo Nordisk terminated the clinical trials for Ocedurenone because it thought they were futile. However, Parexel International (IRL) Ltd (“Parexel“) later “informed Novo that statistical errors had been made in compiling the data”. The judgment also states that:
“The defendants submit that Novo failed to disclose errors in the Futility Determination. After the Futility Determination was made, Parexel had informed Novo that statistical errors had been made in compiling the data. After correcting for the errors, Ocedurenone satisfied only one of two futility criteria (namely, it satisfied the SBP futility criteria but not the p-value futility criteria), such that the ‘anticipated hypothesis’ is that ‘treatment effect is significant but not substantial’, and Ocedurenone was still worth ‘continuing current development plans’ and not ‘worthless’ […]”.
3. Failure to Disclose Information and Documents Provided
The judgment highlights that Novo Nordisk had access to “a full electronic data room with documents from KBP”, which would have allowed Novo Nordisk to conduct its own analysis. These documents included “data on the vital signs of every patient enrolled in Phase 2, identifying the site they were from as well as their [systolic blood pressure (“SBP“)]”. The judgment further states that:
“The defendants allege that Novo failed to disclose the material fact that during due diligence, KBP supplied Novo with raw data in the form of the Vital Signs Data Listing and the CTA Package. Novo did not open these documents, much less request a different format for the data.”
Every pharmaceutical company has a corporate social responsibility to care for patients and address unmet medical needs.
“KBP believes that Novo Nordisk erred in stopping the development of Ocedurenone because it could help patients. KBP intends to make this proof to the tribunal,” said Dr. Huang Zhenhua, founder and chairman of the Company.
KBP has expended significant time and resources into the development of Ocedurenone, and it remains committed to its cause. As such, the Company and Dr. Huang will strive to engage the new management to find a way forward for Ocedurenone, whilst vigorously pursuing their rights in all legal proceedings commenced, including a possible appeal from the decision of the Singapore Court.
All media inquiries can be directed to: info@kbpbiosciences.com
About KBP Biosciences
KBP Biosciences is a global, clinical-stage biotechnology company, headquartered in Singapore, focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet medical needs.
BEIJING, Aug. 13, 2025 /PRNewswire/ — A news report from chinadaily.com.cn
In this documentary, three patients suffered from advanced heart failure share their stories of how China’s independently-developed non-contact full maglev artificial heart brought hope to their lives. Click to learn more!
SEOUL, South Korea, Aug. 12, 2025 /PRNewswire/ — Within the framework of the Vietnam–Korea Economic Forum 2025, and in the presence of Prime Minister of the Republic of Korea Kim Min-seok and General Secretary of the Communist Party of Vietnam Central Committee To Lam, global IT services and technology company FPT signed strategic agreements with ABOV Semiconductor and Gachon University. These partnerships aim to advance semiconductor technology development and foster high-quality human resource training between the two nations.
![]()
Mr. Le Truong Tung, Chairman of FPT University (front row, 5th from left) and Mr. Ha Minh Tuan, Ha Minh Tuan, FPT Software Vice President and FPT Software Korea Chief Executive Officer, FPT Corporation (front row, 6th from left) at the signing ceremony during the Vietnam–Korea Economic Forum 2025 in Seoul
Co-developing Next-Generation Chips with ABOV Semiconductor
FPT’s agreement with ABOV Semiconductor – a leading designer and manufacturer of microcontrollers, advanced nonvolatile memory and various semiconductor solutions – focuses on joint research, design, and development of next-generation chips, while expanding the market and application of semiconductor products in South Korea. The collaboration aims to cooperate in using chips designed by FPT, particularly in South Korean market. They will also collaborate in launching the project regarding collaborative research, design and development of next generation Chips to build into a mutual complementary relationship between their respective technical capabilities and to develop competitive products. As part of the partnership, the Parties will discuss the details and frameworks of FPT’s semiconductor engineering service on a case-by-case basis.
As part of its strategy, FPT aims to build a comprehensive semiconductor ecosystem, from skilled talent to advanced services such as custom IC design, advanced packaging, and semiconductor testing.
High-Tech Human Resource Training with Gachon University
In education, FPT University and Gachon University signed an agreement to promote student exchange and education at both undergraduate and graduate levels, organize joint academic programs, facilitate faculty and scholar exchanges, and share academic information, materials, and publications, along with other academic activities mutually agreed upon by the two universities.
FPT University is a pioneer in Vietnam in training IT professionals in AI, cybersecurity, software engineering, and semiconductor IC design, with programs aligned to industry needs and international standards.
Enhancing Vietnam–Korea Technology Cooperation
Operating in South Korea since 2016, FPT has nearly 2,000 employees working locally and remotely from Vietnam, serving major clients including LG Electronics, LG CNS, Shinhan Bank, Daegu Bank, and Shinsegae I&C. Recognized in Gartner’s Top 200 technology companies in South Korea (2020–2021), FPT Corporation is the leading Vietnamese enterprise in revenue and workforce scale in this competitive market.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam and operates in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. Committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises, the Corporation focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In the first half of 2025, FPT recorded revenue of approximately USD 1.29 billion and profit before tax of around USD 243 million, representing year-on-year growth of 11.4% and 18.5%, respectively. For more information about FPT’s global IT services, please visit https://fpt.com/en
SYDNEY, Aug. 13, 2025 /PRNewswire/ — APSCo Australia, in collaboration with AgeInc, is pleased to announce Aquent, Sirius and Talent Quarter as the first foundation members to commit to the principles of the APSCo Age Inclusive Recruiter program.
Launched this month, the initiative recognises recruiters who demonstrate a strong commitment to fostering an inclusive work environment that values and supports employees of all ages. Participating agencies must commit to educate and train senior leaders and recruitment consultants to improve their knowledge and understanding of age discrimination.
Lesley Horsburgh, CEO, APSCo Australia, said: “We are absolutely delighted to welcome Aquent, Sirius and Talent Quarter as our foundation members and look forward to working with them and other APSCo members to help tackle age discrimination.’ Horsburgh continued, ‘The timing couldn’t be better as new research from AHRI and the AHRC again shows a persistent reluctance by HR managers to hire people aged over 50.’
Danielle Johnson, National Director, Sirius said: “As recruiters, we shape the workforce every day and that comes with a responsibility to lead on inclusion. Signing up to the APSCo Age Inclusive Recruiter program is a natural step for us. We want to make sure our practices reflect the reality that talent comes at every age. This isn’t just about fairness, it’s about giving our clients access to the widest, richest pool of experienced and capable candidates.”
Sue Healy, CEO of Talent Quarter added: “Mature healthcare professionals bring deep clinical knowledge, are calm under pressure, and the mentorship that younger teams rely on. This program helps us challenge outdated biases and ensure every qualified candidate, regardless of age, gets the opportunity to continue to contribute.”
Monique Richards, Managing Director, Aquent said: “The Age Inclusive Recruiter program challenges the bias that’s been limiting workplaces for too long. In a world of talent shortages and as we grapple with an ageing population, overlooking experienced candidates just doesn’t make sense. This program gives us the tools and training, we need to help build workforces that truly reflect the strength of all generations.”
Richard Spencer, Founder of AgeInc concluded: “Ageism is the last socially acceptable form of prejudice in Australian employment, and we’re delighted to partner with APSCo and the wider recruitment industry to help raise awareness of age discrimination in the workplace.’